Edgestream Partners L.P. Sells 28,698 Shares of Moderna, Inc. $MRNA

Edgestream Partners L.P. trimmed its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 84.5% during the first quarter, Holdings Channel.com reports. The firm owned 5,254 shares of the company’s stock after selling 28,698 shares during the period. Edgestream Partners L.P.’s holdings in Moderna were worth $267,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the stock. AQR Capital Management LLC acquired a new position in Moderna during the 1st quarter worth $415,000. NewEdge Advisors LLC increased its stake in shares of Moderna by 732.7% in the 1st quarter. NewEdge Advisors LLC now owns 11,575 shares of the company’s stock valued at $328,000 after buying an additional 10,185 shares during the period. United Services Automobile Association bought a new stake in shares of Moderna during the first quarter worth $230,000. Focus Partners Wealth raised its position in shares of Moderna by 58.7% during the first quarter. Focus Partners Wealth now owns 23,547 shares of the company’s stock worth $668,000 after acquiring an additional 8,706 shares during the last quarter. Finally, American Century Companies Inc. lifted its stake in shares of Moderna by 5.2% during the second quarter. American Century Companies Inc. now owns 48,859 shares of the company’s stock valued at $1,348,000 after acquiring an additional 2,410 shares during the period. 75.33% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Piper Sandler reiterated an “overweight” rating on shares of Moderna in a report on Monday. Wolfe Research restated an “underperform” rating and set a $25.00 target price on shares of Moderna in a research report on Monday, July 20th. The Goldman Sachs Group raised their target price on shares of Moderna from $49.00 to $67.00 and gave the company a “neutral” rating in a research note on Tuesday, July 21st. Citigroup raised their price target on Moderna from $41.00 to $60.00 and gave the stock a “neutral” rating in a research report on Monday. Finally, Royal Bank Of Canada increased their target price on Moderna from $38.00 to $45.00 and gave the company a “sector perform” rating in a research note on Tuesday, July 7th. Three research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and five have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Moderna has an average rating of “Reduce” and a consensus price target of $42.13.

Insider Activity

In other news, President Stephen Hoge sold 53,336 shares of the stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $51.37, for a total transaction of $2,739,870.32. Following the completion of the transaction, the president directly owned 1,483,848 shares in the company, valued at $76,225,271.76. This represents a 3.47% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Thyme Klinger sold 3,471 shares of the firm’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $50.00, for a total value of $173,550.00. Following the completion of the transaction, the insider owned 67,468 shares of the company’s stock, valued at $3,373,400. The trade was a 4.89% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 119,406 shares of company stock worth $5,928,762 over the last ninety days. Insiders own 10.80% of the company’s stock.

Key Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna has begun a Phase 1 human trial of mRNA-1469, an investigational vaccine targeting Bundibugyo ebolavirus. The strain has no licensed vaccine, giving the program potential strategic importance if it demonstrates safety and immune response. The trial is being conducted in Canada with support from the Coalition for Epidemic Preparedness Innovations (CEPI), highlighting the speed and scalability of Moderna’s mRNA platform. Moderna Advances Ebola Vaccine Into Human Testing
• Positive Sentiment: The Ebola program expands Moderna’s pipeline beyond COVID-19 and could address an unmet public-health need, contributing to investor optimism. However, the candidate is only in Phase 1, so commercial success remains several development stages away. Moderna begins first human trial of Bundibugyo Ebola vaccine
• Neutral Sentiment: Brookline Capital Markets raised its 2026 earnings estimates, forecasting a narrower loss of $6.60 per share versus $7.26 previously, and improved its quarterly forecasts. However, it sharply reduced its 2027 estimate to a $3.24 loss from a $0.08 loss, signaling uncertainty about the pace of Moderna’s return to profitability.
• Negative Sentiment: Moderna’s Phase 3 norovirus vaccine trial reportedly showed no early success, raising concerns about another late-stage pipeline setback and weakening confidence in the company’s broader product diversification. No early success for Moderna’s norovirus vaccine in phase 3 trial

Moderna Stock Performance

Shares of Moderna stock opened at $56.26 on Thursday. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.18. The firm has a market cap of $22.46 billion, a price-to-earnings ratio of -7.04 and a beta of 0.91. The stock’s 50-day moving average is $59.91 and its 200-day moving average is $52.99. Moderna, Inc. has a one year low of $22.28 and a one year high of $85.60.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Friday, July 31st. The company reported ($1.97) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.03) by $0.06. The business had revenue of $145.00 million during the quarter, compared to the consensus estimate of $102.93 million. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%.Moderna’s quarterly revenue was up 2.1% on a year-over-year basis. During the same period last year, the company earned ($2.13) earnings per share. Equities analysts predict that Moderna, Inc. will post -4.87 earnings per share for the current fiscal year.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.